ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive: Antiapoptotic protein MCL-1 is reported to be another interesting target in CML, since BCR/ABL expressing cells show higher expression of MCL-1 mRNA and MCL-1 protein, and the use of BCR/ABL inhibitor imatinib results in the decrease of MCL-1 expression in CML cell lines [113].